Evaluation of nutritional parameters that may be associated with survival in patients with locally advanced non-small cell lung carcinoma receiving definitive concurrent chemoradiotherapy: retrospective study conducted in a tertiary pulmonary hospital
- 14 November 2024
- journal article
- research article
- Published by Springer Nature in Japanese Journal of Radiology
- p. 1-12
Abstract
Sarcopenia, defined as skeletal muscle loss, is thought to be a hallmark of cancer cachexia. It has an impact on mortality, especially in cancer patients. There are also opposing views regarding the relationship between definitive concurrent chemoradiotherapy (CRT) and sarcopenia in locally advanced lung cancer. Our aim was to investigate the prognostic effect of sarcopenia in our patients with locally advanced stage III non-small cell lung cancer (NSCLC) who received definitive concurrent CRT by using many markers, and to determine the overall survival (OS). The study was designed as a retrospective cohort. 54 patients with stage III NSCLC who received definitive concurrent CRT at the Radiation Oncology Unit of Health Sciences University Izmir Dr Suat Seren Chest Diseases and Surgery Training Hospital, between January 1, 2018 and December 31, 2019, were included in the study.92% of our patients were sarcopenic with international L3-skeletal muscle index (SMI) and Psoas muscle index (PMI) threshold values. The mean OS time was 32.4 months, and the 4-year survival rate was 38.9%. While the new threshold values specific to our patient group were 26.21 for SMI and 2.94 for PMI, SMI and PMI did not indicate OS with these values. Even with the new values, most proposed criteria for sarcopenia did not indicate OS. However, low BMI (≤21.30), low serum albumin (≤4.24 mg/dl) and low visceral fat tissue area (≤37) in univariate analysis, and low visceral fat tissue area (≤37) in multivariate analysis indicated OS. OS was poor in patients with low fat tissue area. In patients with stage III NSCLC who received definitive concurrent CRT, low visceral fat tissue area (≤37) indicated OS, rather than SMI, PMI and other sarcopenia indices.Keywords
This publication has 42 references indexed in Scilit:
- Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC)Lung Cancer, 2017
- Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysisLung Cancer, 2016
- SarcopeniaCurrent Opinion in Clinical Nutrition and Metabolic Care, 2015
- Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancerActa Oncologica, 2014
- Sarcopenia in Asia: Consensus Report of the Asian Working Group for SarcopeniaJournal of the American Medical Directors Association, 2014
- The assessment and impact of sarcopenia in lung cancer: a systematic literature reviewBMJ Open, 2014
- Prevalence of Sarcopenia and Sarcopenic Obesity in the Korean Population Based on the Fourth Korean National Health and Nutritional Examination SurveysThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2012
- Inequalities in outcomes for non-small cell lung cancer: the influence of clinical characteristics and features of the local lung cancer serviceThorax, 2011
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based studyThe Lancet Oncology, 2008
- Sarcopenia: Origins and Clinical RelevanceThe Journal of Nutrition, 1997